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Long-term survival after allogeneic hematopoietic stem cell transplantation requires intact immuno-
surveillance, which is hampered by lymphoid organ damage associated with conditioning therapy, graft-
versus-host disease, and immunosuppression. Our study aimed to identify the mechanisms contributing to
sustained low memory B cell numbers after transplantation. Peripheral B and T cell subset recovery and
functional marker expression were investigated in 35 acute leukemic patients up to 1 year after trans-
plantation. Apoptosis of B cells after CD40/TLR-9, CD40/BCR, and CD40/BCR/TLR-9-dependent stimulation and
drug efﬂux capacity were analyzed. One half of the patients suffered from infections after day 180. All patients
had strongly diminished CD27þ memory B cells despite already normalized total B cell numbers and fully
recovered CD27IgD memory B cells, putatively of extra-follicular origin. Circulating memory follicular
helper T cells were reduced in the majority of patients as well. Naïve B cells exhibited a decreased expression
of CXCR5, which mediates follicular B cell entry. Additionally, a lower HLA-DR expression was found on naïve
B cells, impairing antigen presentation. Upon CD40/TLR-9edependent activation, B cells underwent signiﬁ-
cantly increased apoptosis paralleled by an aberrant up-regulation of Fas-L on activated T cells and Fas on
resting B cells. Signiﬁcantly increased B cell apoptosis was also observed after CD40/BCR and CD40/BCR/TLR-9
edependent activation. Drug efﬂux capacity of naïve B cells was diminished in cyclosporin Aetreated pa-
tients, additionally contributing to an apoptosis-prone phenotype. We conclude that B cell survival and
migration and T cell communication defects are contributing candidates for an impaired germinal center
formation of memory B cells after allogeneic hematopoietic stem cell transplantation. Follow-up studies
should evaluate effectiveness of revaccinations on the cellular level and should address the long-term
sequelae of B cell defects after transplantation.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) can cure leukemia; however, its success is limited by
incidence of infections, high-grade graft-versus-host diseasedgments on page 1905.
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ty for Blood and Marrow Transplantation.(GVHD), and relapse that contribute to morbidity and mor-
tality after transplantation [1,2]. The conditioning therapy
before transplantation, occurrence of GVHD, and prolonged
immunosuppressive treatment impair the immune recon-
stitution from bone marrow and thymus and the formation
of adaptive immune responses in secondary lymphoid or-
gans. Mechanisms of long-term immune dysfunction remain
to be resolved to enable therapeutic interventions.
A profound B and T cell paucity is found within the ﬁrst
months after allo-HSCT, which is prolonged by the presence
of GVHD directly targeting the bone marrow and thymic
Table 1
Patients’ Clinical Characteristics
Characteristic n ¼ 35
Median age, yr 57
<50 14
50 21
Sex
Female 17
Male 18
Diagnosis
AML 33
ALL 2
Donor
MRD 10
MUD 25
Conditioning therapy
Full-intensity 8
Reduced-intensity 27
ATG 30
Chronic GVHD after d 100
No 23
Grade 1-3 12
Viral reactivation
CMV 14
EBV 3
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MUD,
matched unrelated donor; MRD, matched related donor; CMV, cytomega-
lovirus; EBV, Epstein-Barr virus.
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ized by a strong increase in the number of transitional B cells,
which leave the bone marrow ﬁrst and further differentiate
into recirculating naïve B cells [5].We have shown in patients
that a delayed onset of B cell reconstitution after allo-HSCT
was signiﬁcantly associated with the presence of systemic
acute GVHD, a full-intensity conditioning regimen, and
increased bone marrow T cell inﬁltration [3]. Although B cell
numbers normalize within 1 year after allo-HSCT [1,2],
antigen-experienced B cell subsets, including CD27þIgD
switched and CD27þIgDþIgMþmarginal zoneelike (MZ-like)
memory B cells, remain profoundly diminished [6,7]. Insuf-
ﬁcient vaccination responses, as seen within the ﬁrst year
after transplantation [2], further hint at functional immune
defects. Thus, patients retain a dysfunctional humoral im-
mune system.
Defects in the germinal center (GC) reaction are assumed
to cause the slow recovery of B cell memory, but they are
poorly characterized so far. Deﬁcient CD4þ T cell help due
to the slow recovery of CD4þ T cells was proposed as 1
contributing mechanism [6]. In addition, damage to splenic
and lymph node architecture, particularly in GVHD patients,
has been reported [8,9]. This includes damage to follicular
dendritic cells (FDCs), which are stromal cells that essentially
support the formation of GCs within the B cell follicle by
producing the CXCR5 chemokine CXCL13 and presenting
opsonized antigens to the B cell receptor (BCR) [10]. Although
the immunoglobulin (Ig) repertoire is restricted during the
ﬁrstmonths and normalizeswithin 1 year after allo-HSCT [11],
less diversity from somatic hypermutations remains, thus
further suggesting defects in the GC reaction [12].
Because secondary lymphoid organs in the post-
transplantation course are inaccessible, in depth in vivo
analysis of GC defects is limited in patients. In an attempt to
complement the already existing data on GC defects and to
get a better picture of B cell intrinsic and extrinsic mecha-
nisms potentially contributing to sustained low memory
B cell numbers in allo-HSCT patients, we performed immu-
nological analyses of peripheral B and T cell subset recovery
and their expression of functional markers. Furthermore, we
studied B cell apoptosis after CD40/TLR-9, CD40/BCR and
CD40/BCR/TLR-9-dependent B cell activation and drug efﬂux
capacity of B cells as an intrinsic contributor to B cell survival.
MATERIALS AND METHODS
Patients/Healthy Controls
The study included 35 adult patients diagnosed with acute leukemia.
They received allogeneic hematopoietic grafts obtained by apheresis from
granulocyte colonyestimulating factoretreated HLA-matched related or
unrelated donors. Cyclosporine A (CsA)/methotrexate  antithymoglobulin
(ATG) was given as GVHD prophylaxis to patients with a full-intensity and
CsA/mycophenolate mofetil/ATG to patients with reduced-intensity condi-
tioning regimen. Patients’ characteristics are listed in Table 1. Blood samples
were obtained at days 180 and 360 after allo-HSCT. Ten patients died be-
tween days 180 and 360. Because of the paucity of material, blood samples
from additional acute leukemic patients were collected at days 120 to 180
for the analysis of drug efﬂux capacity (Supplementary Table S1). The clinical
characteristics of both patient cohorts were comparable. The Charité local
ethics committee approved this study (no. EA4/128/09). Patients gave their
informed consent. Healthy controls (HC) were Caucasians with no known
immune deﬁciency and no ongoing infection.
Flow Cytometry
Peripheral blood mononuclear cells (PBMC) from patients and HC
were freshly isolated by Ficoll density gradient centrifugation (Biocholl
separating solution, Biochrom, Germany), and immediately used for the
determination of absolute lymphocyte subsets counts, of functional marker
expression, and of the drug efﬂux capacity by ﬂow cytometry analysis.
Fluorochrome-conjugated anti-human monoclonal antibodies were used forstaining at 4C in PBS/2% Flebogamma (Biotest, Germany; Supplementary
Table S2). Analyses were performed at a LSRII Fortessa Flow Cytometer
(Becton Dickinson, Heidelberg, Germany). Data evaluationwas done with the
FlowJo-9.5.2 software (TreeStar, Ashland, OR, USA). Differential blood counts
were used to determine absolute cell numbers. To exclude differences in
mean ﬂuorescence intensity (MFI) expression levels related to machine set-
tings, the same compensation setup was used for all measurements.
Apoptosis Staining
To perform functional analyses, we resorted to the backup of viable
frozen PBMC samples from patients. For better comparison, samples of HC
were also viable frozen PBMC. Median percentages of Fas-expressing B cells
were comparable before and after freezing of patient PBMCs (before 17%;
after 14%). For CD40/TLR-9-dependent B cell activation, cells were thawed
and stimulated with 10 mg/mL CpG (Invivogen, Toulouse, France) and 1 mg/
mL human recombinant CD40 L (CD40 ligand, R&D Systems, Minneapolis,
MN, USA) in RPMI/10% FCS/1% penicillin/streptomycin (6  106 cells/2 mL)
for 48 hours at 37C, 5% CO2. For CD40/BCR and CD40/BCR/TLR-9-dependent
activation, PBMCs were stimulated for 48 hours with 20 mg/mL F(ab’)2
fragment goat antihuman IgM (Jackson Immunoresearch, Suffolk, UK) in
combinationwith CD40 L or CD40 L and CpG. Necrotic/apoptotic B cells were
determined by Annexin-V FITC (BD Biosciences, Heidelberg, Germany) and
propidium iodide (Biolegend, Fell, Germany) staining for 15 minutes, RT.
Drug Efﬂux Measurement
Freshly prepared PBMC were incubated overnight in Iscove’s Modiﬁed
Dulbecco’s Media (IMDM)/10% human AB-serum/1% penicillin/streptomycin
at 37C, 5% CO2. Then, 5106 cells/approach were incubated with 2.5 mg/mL
rhodamine 123 (R123, Invitrogen, Darmstadt, Germany) in 1.5 mL IMDM/1%
BSA for 20 minutes at 37C. Next, 25 mM CsA (Sigma-Aldrich, Taufkirchen,
Germany) was added after 10 minutes of incubation. After centrifugation,
cell pellets were resuspended in 6 mL IMDM medium only. The 4C
approach was then immediately incubated on ice, whereas 2 incubation
steps at 37C (15 and 40 minutes) with medium exchange in between fol-
lowed for the other approaches. Finally, cells were stained for ﬂow cytom-
etry analysis at 4C.
Luminex Multiplex Cytokine Assay
Plasma diluted with PBS 1:2 was collected from the Ficoll after PBMC
isolation and frozen at 80C until use. Twenty-nine cytokines from the
Milliplex Human Cytokine/Chemokine Magnetic Bead Panel (HCYTOMAG-
60K, Merck Millipore, Darmstadt Deutschland) were simultaneously
assayed with 25 mL of sample based on the Luminex xMAP technology ac-
cording to the manufacturers’ instructions (Luminex; Hertogenbusch, The
Netherlands). Quantiﬁcation was performed at a Bio-Plex 200 system with
the Bio-Plex Manager 6.0 software (Bio-Rad, Hercules, CA).
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Scatter plot depictions with median values are shown. The 2-sided
Mann-Whitney U-test was used for comparisons between 2 groups and
was performed with the GraphPad Prism-v5.0. P values of  .05 were
considered statistically signiﬁcant.
RESULTS
Sustained Low CD27þMemory B Cell and CD4þMemory T
Follicular Helper Cell (TFH) Numbers After Allo-HSCT
Infections with clinical symptoms, typical morphology in
radiological imaging, or pathogen detection were found inFigure 1. Sustained low CD27þmemory B cell and CD4þ TFH cell numbers after allo-H
analyzed for the number of (A) CD19þ B and CD3þ T cells, (B) within CD19þ B cells for t
(DN) B cells and plasmablasts and (C) within CD3þ T cells for the number of CD4þ T he
dots) are given. (D) The percentage of memory CXCR5þ TFH cells within CD3þCD4þ T
representative examples for the gating of CD19þ B cell subsets (CD38hiCD24 plasmabl
B) and the gating of CD4þ T cells within CD3þ T cells (C) and CXCR5þ TFH cells within
signiﬁcant differences between HC and patients are depicted. *P  .05, **P  .001.49% of patients after day 180. CD19þ B cell numbers
normalized in patients at day 360 when compared with age-
matched HC (n ¼ 12; 6 male, 6 female; median age, 53;
range, 40 to 78) (Figure 1A). CD3þ T cells in patients also
reached levels of HC at day 360.
Among CD19þ B cells, CD27IgDþCD38hiCD24hi transi-
tional and CD27IgDþCD38intCD24int/ naïve B cells, which
were the predominating B cell subsets after transplantation,
reached levels of HC at day 360 (Supplementary Figure S1).
CD27þIgDþ MZ-like and CD27þIgD switched memorySCT. PBMCs (HC, n ¼ 12; patients at day 180, n ¼ 33, and day 360, n ¼ 21) were
he number of marginal zone-like (MZ-like), switched memory, double negative
lper cells. Cells/ml blood and median values for HC (squares) and patients (black
cells was determined (HC n ¼ 11, patients at day 360, n ¼ 12). Dot plots show
asts, CD27þIgD switched memory, CD27þIgDþMZ-like, CD27IgD DN B cells,
CD3þCD4þ T cells (D) for a HC and an allo-HSCT patient at day 360. Statistical
Figure 2. Migration and antigen-presenting defects might impair the GC re-
action. The mean ﬂuorescent intensity (MFI) and median values are shown for
the expression of CXCR5, CCR7, and HLA-DR on naïve B cells (HC, n ¼ 11,
squares; patients at day 180, n ¼ 27, circles, and day 360, n ¼ 20, triangles).
Signiﬁcant differences between HC and patients are depicted. *P  .05.
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cell number/mL: MZ-like: HC, 6.7; allo-HSCT, 1.9; P  .01;
switched memory: HC, 15.7; allo-HSCT, 1.3; P  .001)
(Figure 1B), whereas IgDCD27 double negative (DN) B cells
fully recovered until day 360. CD38hiCD24 plasmablasts
normalized in the majority of patients at day 360.
CD3þCD4þ T cells remained diminished at day 360
in patients (median cell number/mL: HC, 890; allo-HSCT, 271;
P  .001) (Figure 1C). CXCR5þ-expressing cells within CD4þ
T cells, representing recirculating memory TFH cells [13],
were signiﬁcantly reduced in the majority of patients at day
360 when compared with those of HC (median %: HC, 9.5;
allo-HSCT, 1.3; P  .05) (Figure 1D).
Numbers of MZ-like, switched memory, DN B cells, and
plasmablasts as well as of CD3þCD4þ T cells at day 360 after
allo-HSCT were comparable in patients who had received full
or reduced-intensity conditioning therapy, with no-ATG or
ATG treatment, with presence or absence of chronic GVHD,
and with no infectious or infectious complications between
day 180 and day 360 (Supplementary Figure S2). Only
CD3þCD4þ T cells were signiﬁcantly decreased in patients
with ATG treatment when compared with patients without
ATG treatment. Percentages of TFH cells were signiﬁcantly
reduced in patients with chronic GVHD compared with pa-
tients without chronic GVHD (Supplementary Figure S2).
Migration and Communication Defects Might Contribute
to Defective GC-Reactions
Decreased numbers of memory B and TFH cells but
normalized DN B cells indicated defects in the GC reaction.
GC defects could be supported by the sustained and signiﬁ-
cantly reduced expression levels of the chemokine receptor
CXCR5 on patients’ naïve B cells at day 360 when compared
with HC (median MFI: HC, 4,223; allo-HSCT, 3,223; P  .001)
(Figure 2), possibly impeding the B cell follicle entry. Mem-
ory B cell subsets also showed decreased CXCR5 expression
levels at day 360 (Supplementary Figure S3A). The expres-
sion of CCR7 on naïve B cells was slightly but not signiﬁcantly
reduced. The HLA-DR expression levels on naïve B cells were
signiﬁcantly lower in patients than those in HC, suggesting a
reduced antigen-presenting function (median MFI: HC,
15,741; allo-HSCT, 6,116). CXCR5, CCR7, and HLA-DR expres-
sion levels on naïve B cells at day 360 after allo-HSCT were
comparable between patient groups with different clinical
conditions (Supplementary Figure S3B-E), except the CCR7
expression was signiﬁcantly higher for patients with ATG
treatment than for patients without ATG treatment.
High B Cell Apoptosis Rate After CD40/TLR-9edependent
B Cell Activation
To investigate functional defects, we analyzed B cell
apoptosis upon CD40/TLR-9-dependent B cell activation.
To distinguish different types/phases of cell death, we
performed Annexin-V and propidium iodide staining
(Figure 3A). Although there was no difference in T cell
apoptosis/necrosis before stimulation, patients’ B cells ten-
ded to more early apoptotic (Annexin-VþPI) B cells
compared with those of HC. After stimulation, more T cells
and signiﬁcantly more B cells were found in the stage of late
apoptosis (Annexin-VþPIþ) for patients at day 360 (B cells,
median %: HC, 9; allo-HSCT, 37; P  .05). Three of the 7
investigated patients had chronic GVHD and all showed
increased late apoptotic B cells when compared with HC,
although clearly increased late apoptotic B cells were only
found for 2 of 4 patients without chronic GVHD (Figure 3B).Stimulation-Induced B Cell Apoptosis is Paralleled by an
Aberrant Up-Regulation of Fas-L on T Cells and Fas on
B Cells
To test for mechanisms of higher susceptibility to
apoptosis, we investigated the expression of Fas and Fas-L on
B and T cells (Figure 4). Patients B cell subsets at day 360
expressed signiﬁcantly higher Fas ex vivo when compared
with that of HC (Figure 4A). Plasmablasts, which showed a
high percentage of Fas-expressing cells in HC, were not
different in patients. Fas expression on total B cells was
comparable between HC and patients at day 360 (median %:
13 versus 15 respectively, data not shown), which can be
attributed to different B cell subset compositions with pre-
dominating naïve and low numbers of memory B cells in
patients. Signiﬁcantly higher Fas expression was found on
MZ-like B cells from patients with a reduced-intensity con-
ditioning therapy than on those from patients with a full-
intensity conditioning therapy, as well as on transitional
B cells in chronic GVHD patients compared with patients
without chronic GVHD (Supplementary Figure S4).
Fas expression on B cells stimulated in vitro with CpG/
CD40L signiﬁcantly increased to a level as seen for HC (me-
dian %, HC: before,11; after, 40; P  .001; allo-HSCT: before,
15; after 40, P  .05) (Figure 4B). Fas expression on CD4þ but
not on CD8þ T cells was signiﬁcantly higher before stimula-
tion for patients than HC (median %: HC, 19; allo-HSCT. 63;
P  .05) (Figure 4B), which was not changed upon stimula-
tion. Patient but not HC CD4þ T cells up-regulated Fas-L
signiﬁcantly upon stimulation (median %, CD4þ: before, 1.2;
after, 3.0; P  .05) (Figure 4C). No signiﬁcant differences in
Fas-L expression were seen on B cells.High B Cell Apoptosis Rate after CD40/BCR and CD40/BCR/
TLR-9-dependent B Cell Activation
CD40 and TLR-9 signaling pathways are important con-
tributors to the T celledependent memory B and plasma cell
formation of BCR-activated B cells within a GC reaction
[14-16]. Therefore, we further investigated B cell apoptosis
after PBMC stimulationwith CpG/CD40L in combinationwith
anti-IgM treatment as well as after CD40L/anti-IgM stimu-
lation, for comparison, to mimic T celledependent B cell
activation as occurs during the GC reaction. For HC, anti-IgM/
CD40L stimulation resulted only marginally in increased
percentages of early (median %: 3 before, 4 after) and late
(3 before, 5 after) apoptotic B cells, which increased with
addition of CpG (9 early, 14 late; Figure 5A). Patients’ B cells,
in contrast, displayed signiﬁcantly higher rates of cells in the
stage of late apoptosis after CD40L/anti-IgM stimulation
Figure 3. High CD40L/CpG stimulationeinduced apoptosis of B cells. PBMCs were stimulated with CpG/CD40L. (A) Shown is the percentage of propidium iodide
(PI)AnnexinVþ early apoptotic, PIþAnnexinVþ late apoptotic and PIþAnnexinV necrotic B (upper graphs) and T (lower graphs) cells (HC, n ¼ 7, black; patients at day
360, n ¼ 7, white) before and after stimulation. (B) B cell apoptosis/necrosis before and after stimulation is given for patients without chronic GVHD (white dots) and
patients with chronic GVHD (grey dots). Lines indicate median values. Dot plots depict representative examples for a HC and a patient after stimulation. Signiﬁcant
differences between HC and patients are given. *P  .05, **P  .001.
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CpG stimulation (83%). The percentage of late apoptotic
B cells before stimulation was comparable to those of HC
(median 3%).
Efﬁcient B cell activation was veriﬁed by assessment of
CD69 expression, which was found at median of 84% of
B cells after CD40L/anti-IgM stimulation and 71% after
CD40L/anti-IgM/CpG stimulation, but only on 4% on B cells
before stimulation for HC (Figure 5B). A median of 84% and
56% of patient B cells expressed CD69 after CD40L/anti-IgM
and CD40L/anti-IgM/CpG stimulation, respectively, which
was not signiﬁcantly different from those of HC.
We observed higher percentages of early apoptotic and
CD69-expressing B cells for the patients with chronic GVHD
than for those without chronic GVHD before stimulation
(Figure 5C,D). After CD40L/anti-IgM and CD40L/anti-IgM/
CpG stimulation, there was a tendency towards higher per-
centages of late apoptotic B cells and lower percentages of
CD69-expressing B cells for patients with chronic GVHD than
for patients without chronic GVHD.A Sustained Inﬂammatory Milieu is Present After Allo-
HSCT
Increased Fas expression on B and CD4þ T cells might
result from a sustained inﬂammatory milieu upon cytotoxic
treatment. Accordingly, B cell subsets, except plasmablasts,
displayed a more activated phenotype at day 180, charac-
terized by signiﬁcantly more CD86-expressing cells (median
%: transitional: HC, 4; allo-HSCT, 15; naïve: HC, 2; allo-HSCT,
11; MZ-like: HC, 5; allo-HSCT, 14; switched memory: HC, 2;
allo-HSCT, 20; DN: HC, 3; allo-HSCT, 20) (Figure 6A). Signif-
icantly more cells expressing the activation/inﬂammation-
induced chemokine receptor CXCR3 were seen for
transitional (HC, 4; allo-HSCT, 8), naïve (HC, 2; allo-HSCT, 6),
switched memory (HC, 9; allo-HSCT. 32), and DN B cells (HC,
9; allo-HSCT, 11) (Figure 6B). CD86 and CXCR3 expression
remained increased on switched memory (CD86: allo-HSCT,
30; CXCR3: allo-HSCT, 31) and DN B cells (CD86: allo-HSCT,
13; CXCR3: allo-HSCT, 11) at day 360.
The activated/inﬂammatory phenotype was accompanied
by an inﬂammatory milieu. The simultaneous analysis of 29
Figure 4. Stimulation-induced B cell apoptosis is paralleled by aberrant Fas/FasL expression. Shown are the percentages and median values of (A) the Fas expression
on CD19þ B cell subsets (HC, n ¼ 12, squares; patients at day 180, n ¼ 27, circles and day 360, n ¼ 21, triangles) and (B,C) the Fas and Fas-L expression on CD3þ,
CD3þCD4þ and CD3þCD8þ T cells and B cells (HC, n ¼ 7, patients day 360, n ¼ 7) before (black) and after (white) PBMC stimulation with CpG/CD40L. Dot plots show
representative examples for the gating of Fas-expressing CD19þ B cells (B) and Fas-L expressing CD3þCD4þ T cells (C) before and after stimulation for a HC and an allo-
HSCT patient at day 360. Signiﬁcant differences between HC and patients and between values before and after stimulation are given. *P  .05, **P  .001.
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the cytokines granulocyte colonyestimulating factor, gran-
ulocyte macrophage colonyestimulating factor, IFNa2, and
TNFa and of the chemokines IP-10, MCP-1, MIP-1b, and
Eotaxin in allo-HSCT patients at day 180 (9 male, 7 female,
median age, 48; range, 24 to 62) than in HC (5male, 5 female,
median age, 42; range, 30 to 59) (Figure 6C). No differences
were obtained for IFNg, IL-1ra, IL-7, and sCD40L. IL-1a, IL-1b,
IL-2, IL-3, IL-4, IL-6, IL-9, IL-10, IL-13, IL-15, IL17A, MIP-1a,
MIP-1b, and TNFb were below the detection limit. IL-5, IL-6,
IL-12, andMCP-3 were detectable only in single patients, and
IL-8 in 9 of 16 patients but in none of the HC (data not
shown). The expression of CD86 and CXCR3 on B cell subsetsat day 360 after allo-HSCT as well as serum cytokine con-
centrations at day 180 after allo-HSCT were comparable be-
tween patients with different clinical conditions
(Supplementary Figure S5).
Decreased Drug Efﬂux Capacity of Naive B Cells in CsA-
Treated Patients
Cytotoxicity of post-transplantation treatments may
contribute to increased susceptibility to apoptosis of B cells
in addition to immunological mechanisms after trans-
plantation. Naïve B cells can extrude toxic substances via
adenosine triphosphate (ATP)-binding cassette transporter
[17]. As CsA is an unspeciﬁc inhibitor of ATP-binding cassette
Figure 5. Increased CD40/BCR and CD40/BCR/TLR-9-induced B cell apoptosis in allo-HSCT patients. PBMCs were stimulated with anti-IgM/CD40L (upper graphs) or
with anti-IgM/CD40L/CpG (lower graphs). (A) The percentages of propidium iodide (PI)AnnexinVþ early apoptotic, PIþAnnexinVþ late apoptotic, and PIþAnnexinV
necrotic B cells and (B) the percentage of CD69-expressing B cells before and after stimulation are given (HC, n ¼ 4, black dots; patients at day 360, n ¼ 7, white dots).
(C,D) Shown are the results of A and B for patients without chronic GVHD (white dots) and with chronic GVHD (grey dots). Lines indicate median values. Signiﬁcant
differences between HC and patients are given. **P  .001.
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drug efﬂux capacity in CsA-treated patients might also
contribute to apoptosis susceptibility of naïve B cells.
Therefore, we obtained blood from additional acute leuke-
mia patients, who were under CsA-treatment, at days 120 to
180 and showed a notable presence of naïve B cells (clinical
characteristics see Supplementary Table S1). We observed a
signiﬁcantly decreased percentage of naïve B cells extruding
the dye R123 for patients compared with those for HC(median percentage R123 naïve B cells: HC, 51; allo-HSCT,
31, P  .05) (Figure 7). No drug efﬂux was seen at 4C
(negative control) and it was strongly diminished with
addition of CsA in both groups.
DISCUSSION
In this study, we were interested in identifying mecha-
nisms that could potentially contribute to sustained memory
B cell paucity after allo-HSCT. Because secondary lymphoid
Figure 6. Increased activated B cell phenotype and inﬂammatory serum cytokines. (A,B) The percentages of CD86-and CXCR3-expressing B cell subsets with median
values are shown (HC, n ¼ 12, squares; patients at day 180, n ¼ 27, circles, and day 360, n ¼ 21, triangles). (C) Levels of indicated inﬂammatory cytokines (upper row)
and chemokines (lower row) in plasma and median values are depicted (HC, n ¼ 10; patients at day 180, n ¼ 16). Statistical signiﬁcant differences between HC and
patients are given. *P  .05, **P  .001.
A. Mensen et al. / Biol Blood Marrow Transplant 21 (2015) 1895e19061902organs are inaccessible in the post-transplantation follow-up
in surviving patients, and also few studies have demonstrated
direct correlations between circulating cells and those found
in lymphoid tissues based on microarray analyses of cellsubsets with similar ﬂow cytometric phenotypes [18,19], we
analyzed peripheral blood B and T cell subset phenotypes and
functionalities to identify clues about lymphocytic defects that
might impair the GC reaction in allo-HSCT patients.
A. Mensen et al. / Biol Blood Marrow Transplant 21 (2015) 1895e1906 1903In accordance with previous studies, we observed a sus-
tained peripheral CD4þ T cell and CD27þ memory B cell
paucity up to 1 year after allo-HSCT [1,6,7,20]. CD4þ T cell
paucity was even more pronounced in ATG-treated patients
than in non-ATGetreated patients, in accordance with our
previously published data [21]. CD27þmemory B cell paucity
was comparable in both groups. Prolonged low CD27þ
memory B cell numbers may simply result from a shorter
history of antigen encounter in patients, but this appears
unlikely, as donor B cells are constantly encountering allo-
antigen. In addition to these ﬁndings, we found a rapid re-
covery of DN B cells. In mice, DN B cells supposedly represent
extra-follicularedeveloping progenitors of CD27þ memory
B cells that fail to go through a GC reaction [22-24]. Thus, the
normalization of DN B cells in our patients could indicate an
intact extra-follicular differentiation pathway, partly
replenishing the B cell memory after transplantation. Normal
numbers of plasmablasts, which derive from GC reactions,
like the deﬁcient CD27þ memory B cells, might argue for a
speciﬁc defect only in the pathway towards memory B cell
generation. Alternatively, these might also derive from extra-
follicular B cells [25].
Decreased memory and increased plasmablast compart-
ment in patients with chronic GVHD have been previously
shown by de Masson et al. [26]. This we could not observe,
which might possibly be attributed to the much later time
point of analysis (mean follow-up, 41 months after HSCT in
patients without chronic GVHD and 44 months in patients
with chronic GVHD). In accordance with our results, Sar-
antopoulos et al. observed no signiﬁcant differences in ab-
solute numbers of CD27þ B cells in patients with andwithout
chronic GVHD [27].
Activated TFH cells were shown in mice to support GC
formation by producing cytokines such as IL-21, which
mediate class-switch recombination and somatic hyper-
mutation of GC B cells and their differentiation into memory
B cells [28]. For the majority of patients and in particular for
chronic GVHD patients, we observed decreased frequencies
of CXCR5þ cells within CD4þ T cells, which supposedly rep-
resents a circulating memory compartment of TFH cells [29].
This indicates that not only quantitatively reduced CD4þ
Tcells but also reduced formation of TFH cells after GC defects
may account for reduced memory B cell formation in pa-
tients. To our knowledge, the frequency of recirculating
memory TFH cells has not been investigated in allo-HSCT
patients before.
Murine TFH and B cells migrate via CXCR5 towards
CXCL13-producing FDCs into the B cell follicle to take part in
the GC reaction [30]. Although the CXCR5 level appeared
normal on TFH cells, we observed signiﬁcantly reduced
CXCR5 levels on naïve and memory B cell in subsets of pa-
tients. CCR7 expression, important for the B cell entry into
the T cell zone of secondary lymphoid organs, was slightly
reduced on naïve B cells. Because decreased levels of CXCR5
and CCR7 on B cells have been associated with reduced
migration capacity towards the respective ligands CXCL13
and CCL21 in humans [31], lower CXCR5 expression on naïve
B cells in our patients could suggest an impaired migration
capacity into the B cell follicle and consequently reduced
participation in GC reactions.
In mice, the interaction of naïve CD4þ T cells with
antigen-presenting B cells contributes to priming of TFH cells
and maintains TFH cell responses and, thereby, GC formation
of memory B cells [32-34]. We observed signiﬁcantly
reduced HLA-DR expression on naïve B cells, which couldimpair B-T cell interaction within a GC reaction because of a
reduced antigen-presenting function towards CD4þ T cells.
This could further contribute to the lower number of mem-
ory TFH cells in our patients.
Strikingly, patients’ B cells at day 360 displayed a 3-fold
higher apoptosis rate compared with those of HC when
stimulating PBMCs with CD40 L and CpG. Additionally, T cells
also displayed increased apoptosis in this stimulation setting,
hinting at multiple survival defects that could possibly
impair the GC reaction of patients. Increased B cell apoptosis
may be attributed to increased numbers of immature tran-
sitional B cells, which are likelymore prone to apoptosis than
mature B cells are. However, at day 360, mature naïve B cells
were predominating in all patients so that differences in
apoptosis rates between HC and patients are unlikely to be
caused by an immature B cell state in patients only. Impor-
tantly, we observed profoundly increased apoptosis of pa-
tient B cells after CD40L/anti-IgM stimulation, which was
further increased by addition of CpG. These stimulations
mimic the T celledependent B cell activation as occurring
during the GC reaction. CD40 signaling has been shown in
mice deﬁcient for CD40 or CD40L to be critical for
T celledependent Ig class switching, GC differentiation, and
formation of memory B cells and long-lived plasma cells of
BCR-activated B cells [14,15]. TLR-9 signaling enhances
T celledependent antibody responses of BCR-activated
B cells at multiple stages of the GC reaction, such as by
increasing the number of TFH cells and GC B cells and by
augmenting class switch to IgG2a, afﬁnity maturation, and
memory antibody responses [16].
CD40/TLR-9, CD40/BCR, and CD40/BCR/TLR-9 stimulatione
induced death of B cellswas evenmore pronounced inpatients
with chronic GVHD than in thosewithout chronic GVHD. Allen
et al. has shown increased survival rates and an increased
metabolic state of B cells in patients with active chronic GVHD
compared with in patients without chronic GVHD [35]. How-
ever, these authors only investigated spontaneous apoptosis
but not B cell activationeinduced cell death. Whether the
increased activation-induced cell death, whichwe observed, is
associated with a hyperactivated state of B cells in chronic
GVHD patients remains to be elucidated. Increased CD69
expression on B cells from chronic GVHD patients before
stimulation might support an increased activation status of
B cells in chronic GVHD patients, whereas decreased per-
centages of CD69-expressing B cells after stimulation could be
explained by rapid apoptosis of activated B cells.
To better understand the higher susceptibility to
apoptosis, we determined Fas/Fas-L expression on B and
T cells during stimulation with CpG/CD40L. In mice, Fas
expression on activated GC B cells is an important negative
regulator of B and T cell survival [36]. High expression of Fas
on murine GC B cells has been shown to be associated with
susceptibility to Fas-mediated apoptosis in vitro [37]. In line
with that, Fas ablation in murine GC B cells resulted in fatal
B and T cell proliferation and increased memory B cell for-
mation, which was prevented by blocking B-T cell interaction
and GC formation [36]. We observed signiﬁcantly increased
Fas expression on B and CD4þ T cells ex vivo, suggesting a
higher susceptibility of both subsets to apoptosis. For B cells,
higher Fas expression might further indicate an increased
activation status, as Fas was signiﬁcantly up-regulated upon
stimulation, which is known to occur after T celledependent
activation via CD40 signaling. Althoughwe observed a strong
Fas up-regulation on B cells from patients and HC, Fas-L was
signiﬁcantly up-regulated only on CD4þ T cells of the
Figure 7. Decreased B cell drug efﬂux capacity in CsA-treated patients.
Representative examples for R123-(efﬂuxing) naïve B cells at 4C (negative
control), 37C, and 37C þ CsA are shown for an HC and patient at D120.
Below, the percentages of R123 naïve B cells and median values are depicted
(HC, n ¼ 9, squares; patients at D120-180, n ¼ 6, dots). Statistical signiﬁcant
differences between HC and patients are given. *P  .05.
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subsets before stimulation, this could explain the increased
apoptosis susceptibility of patient B cells. BCR and TLR-9
signaling have been shown to collaborate in rescuing
B cells from Fas-induced apoptosis [38]. Whether patient
B cells differ in Fas-induced pro-apoptotic or BCR/TLR-9 in-
duces anti-apoptotic signaling events might be an important
indication for future investigations. Increased Fas-FasL
interaction during T celledependent B cell activation could
potentially contribute to decreased GC memory B cell for-
mation in allo-HSCT patients. This is in line with a previous
study, showing decreased Ig-production after in vitro stim-
ulation of B cells in the presence of T cells, suggesting defects
in T cell helper or T cell suppressor activity in allo-HSCT pa-
tients [39].
In a murine allogeneic transplantation model, B cell
paucity was signiﬁcantly reduced in recipients of Fas-
Ledeﬁcient donor T cells, suggesting a role of the Fas-FasL
system in lymphoid hypoplasia [40]. Inﬂammatory cyto-
kines, such as IFNg and TNFa, are increased after allo-HSCT
in patients [41-43] and contribute to the up-regulation of
Fas on lymphocyte progenitors in bone marrow [44,45].
One half of a year after transplantation, we could still
detect elevated plasma levels of inﬂammatory cytokines
and chemokines, including TNFa, MCP-1, and IP-10. These
had been shown before to be elevated within the ﬁrst
100 days after allo-HSCT but have not been investigated at
later time points [42,46]. Thus, a sustained inﬂammatory
status might support Fas-L expression on (allo)-activated
T cells and Fas expression on B cells, rendering them more
susceptible to apoptosis. Interestingly, we further found
that naïve B cells in CsA-treated patients displayed
decreased drug efﬂux capacity. This might suggest that not
on only immunological mechanisms but also treatment-
associated cytotoxicity after inhibition of drug efﬂux ca-
pacity by immunosuppressive treatment might render
naive B cells intrinsically more “fragile” and more sus-
ceptible to apoptosis. This, in turn, could reduce the
number of naïve B cells potentially participating in the GC
reaction.
CONCLUSIONS
The results of our analyses on peripheral B and T cell
phenotypes and functionalities reveal multiple lympho-
cytic defects that could, if similarly found within secondary
lymphoid organs, impair the GC-dependent generation of
memory B cells at different stages in patients who have
undergone transplantation, thus providing a basis for
investigation in murine transplantation models. We pro-
pose the following model (Figure 8). B cells in a more
apoptosis-prone state and functional defects in the GC-
reaction cause persistent memory B cell paucity and,
thus, susceptibility to infections 1 year after HSCT.
Decreased naïve B cell drug efﬂux capacity as a result of
immunosuppression and increased Fas expression on naïve
B and CD4þ T cells due to persistent inﬂammation renders
both participants of GC-reactions pro-apoptotic. Within
secondary lymphoid organs, decreased CXCR5 levels on
B cells impair proper migration into the B cell follicle to-
wards CXCL13-producing antigen-presenting FDCs, thus
effectively impairing GC induction. As a consequence of low
CD4þ T cell numbers due to impaired thymic activity, CD4þ
T cell priming by dendritic cells and formation of effector T
helper and pre-GC TFH cells occur less frequently. Pre-GC
TFH cells normally migrate to the T-B cell border tointeract with antigen-activated B cells. Furthermore,
decreased HLA-DRedependent antigen presentation by
B cells impairs the maintenance of TFH cells. Increased BCR/
CD40/TLR-9 signalingeinduced apoptosis of B cells during
T celledependent B cell activation leads to reduced GC
formation of memory B cells and might potentially be
attributed to an aberrant up-regulation of Fas-L on acti-
vated CD4þ T cells The extra-follicular non-GC differentia-
tion of DN B cells may be not affected.
Our data emphasize the careful consideration of
comprehensive anti-infectious prophylactic treatment even
1 year after allo-HSCT, a control of vaccination responses at
immune cell level, and the assessment of adoptive memory
B cell transfer as a treatment strategy to support the immune
function after transplantation.
Figure 8. Proposed model of defects contributing to sustained memory B cell paucity. On the left, homeostatic condition without presence of an antigen and on the
right in presence of an appropriate antigen. By Demski Design.
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